Based on 10 analysts giving stock ratings to Pyxis Oncology Inc in the past month.
In the current month, PYXS has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. PYXS average Analyst price target in the last month is 8.556.
Based on analysts' estimates, PYXS EPS is projected to reach -0.223 in FY2026Q4, following reported EPS of -0.239 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.24, while Pyxis Oncology IncPYXS's earnings per share (EPS) for the previous quarter was USD -0.40. EPS for the next quarter is expected at USD -0.22.